| Study | Reason for exclusion |
|---|---|
| Nogueira 2007 | An open‐label feasibility study of high dosages of the endothelin receptor antagonist bosentan (ETA/B) in SAH patients at high‐vasospasm risk |
SAH: subarachnoid hemorrhage
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.